XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $748 | -100.0% | 21,900 | -85.5% | 0.00% | -80.0% |
Q1 2022 | $4,609,000 | -61.3% | 150,777 | -60.4% | 0.01% | -66.7% |
Q4 2021 | $11,899,000 | +25.8% | 380,877 | -38.5% | 0.02% | +25.0% |
Q3 2021 | $9,459,000 | -22.8% | 619,077 | -5.9% | 0.01% | -20.0% |
Q2 2021 | $12,252,000 | -1.2% | 657,977 | -5.1% | 0.02% | 0.0% |
Q1 2021 | $12,404,000 | +4.7% | 692,977 | -10.0% | 0.02% | +15.4% |
Q4 2020 | $11,842,000 | +18.4% | 769,977 | -14.8% | 0.01% | +30.0% |
Q3 2020 | $9,999,000 | -23.0% | 903,277 | -12.8% | 0.01% | -9.1% |
Q2 2020 | $12,982,000 | +45.3% | 1,035,277 | +31.4% | 0.01% | +22.2% |
Q1 2020 | $8,937,000 | +14.4% | 788,077 | +32.3% | 0.01% | +50.0% |
Q4 2019 | $7,809,000 | +77.4% | 595,677 | +21.9% | 0.01% | +50.0% |
Q3 2019 | $4,402,000 | -6.1% | 488,600 | +2.8% | 0.00% | 0.0% |
Q2 2019 | $4,688,000 | -2.3% | 475,500 | +0.7% | 0.00% | 0.0% |
Q1 2019 | $4,799,000 | +34.4% | 472,300 | -16.5% | 0.00% | 0.0% |
Q4 2018 | $3,570,000 | -48.7% | 565,700 | +7.3% | 0.00% | -42.9% |
Q3 2018 | $6,961,000 | +17.7% | 527,337 | -32.2% | 0.01% | +133.3% |
Q2 2018 | $5,914,000 | +319.1% | 777,500 | +170.0% | 0.00% | +50.0% |
Q1 2018 | $1,411,000 | +100.7% | 288,000 | +15.7% | 0.00% | +100.0% |
Q4 2017 | $703,000 | +52.5% | 249,000 | +59.2% | 0.00% | 0.0% |
Q3 2017 | $461,000 | +12.4% | 156,400 | +20.0% | 0.00% | 0.0% |
Q2 2017 | $410,000 | -52.8% | 130,300 | -40.0% | 0.00% | 0.0% |
Q1 2017 | $868,000 | -1.3% | 217,090 | +90.1% | 0.00% | 0.0% |
Q4 2016 | $879,000 | +12.8% | 114,200 | +18.7% | 0.00% | 0.0% |
Q3 2016 | $779,000 | +172.4% | 96,200 | +98.4% | 0.00% | 0.0% |
Q2 2016 | $286,000 | +21.2% | 48,500 | +43.5% | 0.00% | – |
Q1 2016 | $236,000 | -24.8% | 33,800 | -13.6% | 0.00% | -100.0% |
Q4 2015 | $314,000 | +85.8% | 39,105 | +90.8% | 0.00% | – |
Q3 2015 | $169,000 | -65.1% | 20,500 | -51.2% | 0.00% | -100.0% |
Q2 2015 | $484,000 | – | 42,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |